DOCSLIB.ORG

Downloaded Or Used a Contact Tracing/Exposure Notification App (77%) and Who Would Not Receive a COVID-19 Vaccine When Available (20%) Or Were Unsure (12%)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloaded Or Used a Contact Tracing/Exposure Notification App (77%) and Who Would Not Receive a COVID-19 Vaccine When Available (20%) Or Were Unsure (12%) COVID-19 Evidence Support Team EVIDENCE SEARCH REPORT Review Question: How effective are COVID-19 vaccines? Context: Benefits following dose/second dose; how well it prevents infections; evidence of limiting viral replication or spread; preventing hospitalization; preventing ventilation; preventing “long COVID” (long term symptoms), duration of immunity (natural and vaccinated). FDA cold chain changes. Effectiveness against P1 variant. Booster doses for variants. Does not include vaccine willingness/acceptance (to be run as a separate search) Review Code: INF031801v3 ESR Complete Date: April 30, 2021 Cite As: Miller, L., Howell-Spooner, B.. How effective are COVID-19 vaccines? 2021 Apr 30, Document no.: INF031801v3 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 107 p. (CEST evidence search report). Librarian Notes & Comments Hello All, We’ve run this update for the databases from March 18th to April 30th, and searched for grey literature between those dates as well. Thanks, Brianna and Lukas Search Results: Guidelines, Summaries & Other Grey Literature Government Health Canada Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply. April 14, 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee- on-immunization-naci/extended-dose-intervals-covid-19-vaccines-early-rollout-population- protection.html Public Health Agency of Canada Disclaimer This information is provided as a service by the Saskatchewan Health Authority and University of Saskatchewan Libraries. Professional librarians conduct searches of the literature. Results are subject to the limitations of the databases and the specificity, broadness and appropriateness of the search parameters presented by the requester. The Libraries do not represent in any matter that retrieved citations are complete, accurate or otherwise to be relied upon. The search results are only valid as of the date and time at which the search is conducted. The Libraries do not accept responsibility for any loss or damage aris ing from the use of, or reliance on, search results. Statement from the Council of Chief Medical Officers of Health (CCMOH) on the use of AstraZeneca COVID-19 Vaccine. April 23, 2021. https://www.canada.ca/en/public- health/news/2021/04/ccmoh-statement-on-use-of-astrazeneca-covid-19-vaccine.html ECDC Infographic: COVID-19 vaccination in the EU/EEA. April 29, 2021. https://www.ecdc.europa.eu/en/publications-data/infographic-covid-19-vaccination-eueea Objectives of vaccination strategies against COVID-19. April 23, 2021. https://www.ecdc.europa.eu/en/publications-data/objectives-vaccination-strategies-against- covid-19 Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions. April 21, 2021. https://www.ecdc.europa.eu/en/publications-data/interim-guidance-benefits-full-vaccination- against-covid-19-transmission ECDC guidance for adjusting non-pharmaceutical interventions based on vaccination status. April 21, 2021. https://www.ecdc.europa.eu/en/news-events/ecdc-guidance-adjusting-non- pharmaceutical-interventions-based-vaccination-status Agency for Clinical Innovation (ACI) and the New South Wales Government COVID-19 vaccines and clotting disorders. April 30, 2021. https://aci.health.nsw.gov.au/__data/assets/pdf_file/0005/646547/Evidence-check-COVID-19- vaccines-clotting-disorders.pdf Cerebral venous sinus thrombosis after AstraZeneca vaccination. April 30, 2021. https://aci.health.nsw.gov.au/__data/assets/pdf_file/0006/646548/Eveidemce-check-Heparin- CVST-COVID-19-vaccines.pdf Immunocompromised patients and COVID-19 vaccines. April 28, 2021. https://aci.health.nsw.gov.au/__data/assets/pdf_file/0009/645750/Evidence-check- Immunocompromised-patients-COVID-19-vaccines.pdf Public Health England Public Health England vaccine effectiveness report. March 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat a/file/971017/SP_PH__VE_report_20210317_CC_JLB.pdf Impact of COVID-19 vaccines on mortality in England December 2020 to March 2021. March, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat a/file/977249/PHE_COVID-19_vaccine_impact_on_mortality_March.pdf CDC Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members — Chicago, Illinois, December 2020–March 2021. April 30, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e1.htm?s_cid=mm7017e1_w COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021. April 30, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e2.htm?s_cid=mm7017e2_w Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Evidence Search Report: INF031801v3 ESR 2 Thrombocytopenia Syndrome Among Vaccine Recipients – United States, April 2021. April 30. 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e4.htm?s_cid=mm7017e4_x Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged 65 Years – United States, January – March 2021. April 28, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm?s_cid=mm7018e1_x What You Should Know About the Possibility of COVID-19 Illness After Vaccination. April 21, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure- effectiveness/breakthrough-cases.html NHS Library and Knowledge Services Type of COVID -19 antibodies after vaccination compared with after COVID-19 infection. January 14, 2021. https://kfh.libraryservices.nhs.uk/covid-19-coronavirus/for-lks-staff/literature- searches/ Research Centres Science Table COVID-19 Advisory for Ontario A Vaccination Strategy for Ontario COVID-19 Hotspots and Essential Workers. April 23, 2021. https://covid19-sciencetable.ca/sciencebrief/a-vaccination-strategy-for-ontario-covid-19- hotspots-and-essential-workers/ National Collaborating Centre for Methods and Tools Rapid Review: Post Vaccination Transmission. March 26, 2021. https://www.nccmt.ca/covid- 19/covid-19-evidence-reviews/412 Prevent Pandemics Weekly Science Review March 18 – April 16, 2021. April 15, 2021. https://preventepidemics.org/covid19/science/weekly-science-review/march-18-april-16- 2021/#FAQ:__Should_pregnant_people_get_a_COVID-19_vaccine Centre for Economic Policy Research DP16070 The Great COVID-19 Vaccine Rollout: Behavioral and Policy Responses. April, 2021. https://cepr.org/active/publications/discussion_papers/dp.php?dpno=16070 Search Results: News, Blogs, & Social Media Press Releases Public Health England One dose of COVID-19 vaccine can cut household transmission by up to half. April 28, 2021. https://www.gov.uk/government/news/one-dose-of-covid-19-vaccine-can-cut-household- transmission-by-up-to-half Evidence Search Report: INF031801v3 ESR 3 News CBC Does the AstraZeneca vaccine cause more common side-effects than others? Your coronavirus questions answered. April 28, 2021. https://www.cbc.ca/news/health/ask-covid-astrazeneca- genx-side-effect-1.6003923 What Johnson & Johnson’s 1-shot vaccine could mean for Ontario’s most vulnerable. April 28, 2021. https://www.cbc.ca/news/canada/toronto/johnson-johnson-vaccine-ontario-vulnerable- 1.6004021 Do vaccines prevent transmission? Should physical distancing be increased? Your COVID-19 questions answered. April 25, 2021. https://www.cbc.ca/radio/checkup/is-it-time-to-make- police-body-cameras-mandatory-1.6001107/do-vaccines-prevent-transmission-should-physical- distancing-be-increased-your-covid-19-questions-answered-1.6001919 Canadians over 30 should be offered AstraZeneca-Oxford vaccine, advisory body recommends. April 23, 2021. https://www.cbc.ca/news/health/astrazeneca-covid-19-vaccine-over-30-naci- 1.6000052 Health Canada to start real-time review of Medicago COVID-19 vaccine. April 23, 2021. https://www.cbc.ca/news/health/health-canada-to-start-real-time-review-of-medicago-covid- 19-vaccine-1.5999559 Quebec is planning to use a different vaccine for the 2nd dose in some cases. Here’s what the experts say. April 23, 2021. https://www.cbc.ca/news/canada/montreal/quebec-second-dose- moderna-pfizer-1.5998847 U.S. to resume use of Johnson & Johnson COVID-19 vaccine. April 23, 2021. https://www.cbc.ca/news/health/us-panel-restart-johnson-and-johnson-vaccinations- 1.6000464 Unvaccinated care-home workers a bigger threat than family visits, Sask. health official says. April 23, 2021. https://www.cbc.ca/news/canada/saskatoon/unvaccinated-care-home-workers- a-bigger-threat-than-family-visits-sask-health-official-says-1.6000091 Here’s what’s known about why women seem more susceptible to rare vaccine blood clots. April 20, 2021. https://www.cbc.ca/news/health/vaccines-covid-blood-clots-research-1.5989719 How a COVID-19 vaccine can (and cannot) affect menstruation, mammograms and more. April 19, 2021. https://www.cbc.ca/news/canada/british-columbia/women-covid-vaccines-1.5991026 Sask. ‘actively reviewing’ dropping age eligibility for AstraZeneca vaccine to 40: Moe. April 19, 2021. https://www.cbc.ca/news/canada/saskatoon/saskatchewan-covid-19-vaccine-scott-moe- 1.5993363 Ontario, Alberta to lower minimum age for AstraZeneca-Oxford COVID-19 vaccine to 40 from 55.
Load more

Recommended publications
  • The Epidemiology of COVID-19 in Canada in 2020: the Pre-Vaccine Era February 2021
    The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era February 2021 An RSC Policy Briefing The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era An RSC Policy Briefing Authors Wendy Sligl (Chair) University of Alberta David Waldner University of Alberta Jennie Johnstone University of Toronto Robyn Harrison University of Alberta Duncan Webster Dalhousie University Lynora Saxinger University of Alberta Peer Review Monitor Tom Marrie, FRSC Dalhousie University Peer Reviewers Nick Daneman University of Toronto Rob Fowler University of Toronto Srinivas Murthy The University of British Columbia David Patrick The University of British Columbia Dan Reid Dalhousie University Robert Strang Chief Medical Officer of Health, Nova Scotia Suggested citation for Policy Briefing Report: Waldner D, Harrison R, Johnstone J, Saxinger L, Webster D, Sligl W. The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era. Royal Society of Canada. 2021 Cover Art Christine De Vuono, For Your Own Good, (2020) Over the course of the pandemic, those in long term care facilities have been hit hardest with the impact of COVID-19 outbreaks. The response has been to lock down care homes and ban visitors, volunteers and even care packages, as attempts to stop the virus from entering the facility. This had the unintended, but very real consequence of isolating our most vulnerable from those who care for and love them. “For Your Own Good”, made of 100 carved figures from identical bars of soap, then placed in mason jars, which in turn are placed on shelves, allow us to look in on the miniature elderly figures, who look out at us.
    [Show full text]
  • Celebrating 100 Years
    AMERICANa CERAMICting SOCIETY ars Celebr 100 ye bulletinemerging ceramics & glass technology JUNE/JULY 2021 Student perspectives on facing uncertainty New issue inside: JUNE/JULY 2021 • VOLUME 2 • ISSUE 2 www.ceramics.org/ceramicandglassmanufacturing PREPARING FOR CONTINGENCIES HELPED COMPANIES GROW DURING THE PANDEMIC THE ROCKY ROAD BACK TO ‘LIVE’: IMPACT OF THE PANDEMIC FROM A TRADE SHOW PERSPECTIVE Materials Genome Initiative at 10 years | 2021-2022 ACerS Board members and directors When it Comes to Heat, We Sweat the Details! Your firing needs are unique. Our laboratory can run tests to So why use an “off the shelf” help identify your process kiln in your process? boundaries. Through our toll firing facility, we can At Harrop, we get it. help to further define That’s why, for over a the equipment/ century, we’ve been processing putting in the hard work combination that to design and service works best for your custom kilns. Is it harder material. And if you to do things this way? are not ready for a Yes. Is the extra effort new kiln, we can toll worth it? You bet! fire your material to help meet your At Harrop, we don’t production needs. stop there. If you aren’t sure what you Does your current need, we can help. kiln company sweat the details? www.harropusa.com 1.614.231.3621 Harrop Ad Sweat the Details ACerS Full Size w 100 logo.indd 1 5/21/20 9:33 AM contents June/July 2021 • Vol. 100 No.5 feature articles department News & Trends . 3 Materials Genome Initiative 10 years later: Spotlight .
    [Show full text]
  • Effectiveness of Bnt162b2 and Mrna-1273 Covid-19 Vaccines BMJ: First Published As 10.1136/Bmj.N1943 on 20 August 2021
    RESEARCH Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines BMJ: first published as 10.1136/bmj.n1943 on 20 August 2021. Downloaded from against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study Hannah Chung,1 Siyi He,1 Sharifa Nasreen,1 Maria E Sundaram,1,2 Sarah A Buchan,1,2,3,4 Sarah E Wilson,1,2,3,4 Branson Chen,1 Andrew Calzavara,1 Deshayne B Fell,1,5,6 Peter C Austin,1,7 Kumanan Wilson,5,8,9 Kevin L Schwartz,1,2,3 Kevin A Brown, 1,2,3 Jonathan B Gubbay,3,10 Nicole E Basta,11 Salaheddin M Mahmud,12 Christiaan H Righolt,12 Lawrence W Svenson,13,14,15,16 Shannon E MacDonald,15,17 Naveed Z Janjua,18,19 Mina Tadrous,1,20,21 Jeffrey C Kwong,1,2,3,4,22,23 on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators For numbered affiliations see ABSTRACT received at least one dose of vaccine. Among end of the article OBJECTIVE participants who tested positive, 2479 (4.7%) were Correspondence to: J Kwong To estimate the effectiveness of mRNA covid-19 admitted to hospital or died. Vaccine effectiveness [email protected] vaccines against symptomatic infection and severe against symptomatic infection observed ≥14 days (or @DrJeffKwong on Twitter ORCID 0000-0002-7820-2046) outcomes (hospital admission or death). after one dose was 60% (95% confidence interval Additional material is published DESIGN 57% to 64%), increasing from 48% (41% to 54%) at online only.
    [Show full text]
  • Top 10 Stories from the June 2021 AMA Special Meeting
    Top 10 stories from the June 2021 AMA Special Meeting JUN 17, 2021 Kevin B. O'Reilly News Editor Nearly 700 physicians, residents and medical students gathered for the June 2021 AMA Special Meeting of the AMA House of Delegates (HOD) to consider a wide array of proposals to help fulfill the AMA's core mission of promoting medicine and improving public health. As they have done since the global pandemic was declared last year, the delegates met virtually. Pandemic heroism sets path for work ahead “This is a consequential time in American history, and in the history of medicine,” new AMA President Gerald E. Harmon, MD, said in his inaugural address. The nation is “at war against seemingly formidable adversaries: the COVID-19 pandemic, which has led to the deaths of millions worldwide, and hundreds of thousands here at home, prolonged isolation and its effects on emotional and behavioral health, political and racial tension, and the immense battle to rid our health system—and society—of health disparities and racism.” Watch or read Dr. Harmon’s speech. Susan R. Bailey, MD, now the AMA’s immediate past president, told delegates that “no one has shouldered more in this pandemic than our courageous colleagues on the front lines—brave men and women from every state who have gone above and beyond in service to their patients and communities. You will remain in our hearts and in our thoughts long after this pandemic is over.” Watch or read Dr. Bailey’s speech. Executive Vice President and CEO James L. Madara, MD, detailed the role “a more nimble, focused” AMA played in supporting physicians during a once-in-a-generation public health crisis and how that response can be channeled to advance health equity.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Storage Best Practices for Frozen Vaccines-Fahrenheit
    Storage Best Practices for Frozen Vaccines–Fahrenheit (F) 1 Unpack vaccines immediately 1. Place the vaccines in trays or containers for proper air flow. 2. Put vaccines that are first to expire in front. HEP A - VFC 3. Keep vaccines in original boxes with lids closed to prevent exposure to light. 4. Separate and label vaccines by type and public (VFC) or private. 2 Thermostat should be at the factory-set or midpoint temperature setting Frozen Vaccines Too Cold! Within Range Too Warm! Take Action! Take Action! Report out-of-range temperatures immediately! -70° F -65° F -60° F -50° F -45° F -40° F -35° F 10° F 15° F -58° F 5° F 3 Use vaccine storage best practices Freezer Only DO temp range ✓ Do make sure the freezer door is closed! -58° F to 5° F ✓ Do use water bottles to help maintain consistent temperature. ✓ Do leave 2 to 3 inches between vaccine containers and freezer walls. don’t block vents ✓ Do post “Do Not Unplug” signs on freezer and by electrical outlet. do not unplug DON’T Don’t use dormitory-style refrigerator/freezer. Don’t use combo refrigerator/freezer unit. Don’t put food in freezer. Don’t store vaccines on shelves in freezer door. CS243541-D Revision December 2020 Distributed by Visit www.cdc.gov/vaccines/SandH or contact your state health department for more information. Test Your Knowledge 1 Which of the following units is the best for storing frozen vaccines? Freezer Freezer Freezer Freezer A. Full-size B. Full-size C. Stand-alone D.
    [Show full text]
  • Frequently Asked Questions About COVID-19
    doh.sd.gov/covid/ Frequently Asked Questions About COVID-19 VACCINE SAFETY Why should I get vaccinated for COVID-19? COVID-19 can cause serious illness or even death. There’s no way to know how COVID-19 will affect you. And if you get sick, you could spread the disease to friends, family, and others around you, putting their lives at risk. Getting a COVID-19 vaccine greatly reduces the risk that you’ll develop COVID- 19. The vaccines prevent nearly 100% of hospitalizations and deaths due to COVID-19. Are the COVID-19 vaccines safe? Yes. The COVID-19 vaccines available in the United States meet the FDA’s rigorous standards for safety and effectiveness. Tens of millions of people in the United States have received COVID-19 vaccines, and all COVID vaccines will continue to be monitored for safety. Serious health effects from vaccines are very rare. It’s highly unlikely that COVID-19 vaccines will cause long-term health problems. Also, there is no evidence at all that they will cause infertility or cancer. Your risk for serious health problems is much lower from the vaccine than your risk if you’re unvaccinated and get COVID-19. COVID-19 can leave you with heart and lung damage and other conditions that require long-term treatment. Vaccines are much safer paths to immunity than the disease itself. How can COVID-19 vaccines be safe since they were developed so fast? Safe COVID-19 vaccines were developed quickly through the use of a century of vaccine experience; technology that was new to vaccines but had been studied for two decades; a coronavirus vaccine already in development at the National Institutes of Health; and tens of thousands of volunteers for clinical trials that enabled rapid accumulation of data on safety and effectiveness.
    [Show full text]
  • CDC Vaccine Storage and Handling Guide
    Table of Contents General Information Vaccine Storage and Handling Best Practices 5 Selected Biologicals Diphtheria Toxoid-, Tetanus Toxoid- and acellular Pertussis-Containing Vaccines DTaP: DAPTACEL, Infanrix, Tripedia 11 DTaP-IPV: KINRIX 11 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV/Hib: Pentacel 11 Haemophilus influenzae type b-Containing Vaccines Hib: ActHIB, Hiberix, PedvaxHIB 15 Hib-HepB: Comvax 15 DTaP-IPV/Hib: Pentacel 11 Hepatitis-Containing Vaccines HepA: Havrix, VAQTA 19 HepB: Engerix-B, Recombivax HB 19 HepA-HepB: Twinrix 19 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-HepB-IPV: Pediarix 11 Hib-HepB: Comvax 15 Human Papillomavirus Vaccines HPV2: Cervarix 23 HPV4: Gardasil 23 Vaccine Storage and Handling Guide —————————————————————————————— Page 2 Table of Contents Influenza Vaccines LAIV: FluMist 27 TIV: Afluria, Fluarix, FluLaval, Fluvirin, Fluzone, Fluzone High-Dose, Fluzone Intradermal 29 Measles-, Mumps- and Rubella-Containing Vaccine MMR: M-M-RII 33 MMRV: ProQuad 69 Meningococcal Vaccines MCV4: Menactra, Menveo 37 MPSV4: Menomune 41 Pneumococcal Vaccines PCV13: Prevnar 13 45 PPSV23: Pneumovax 23 45 Poliovirus-Containing Vaccine IPV: IPOL 49 DTaP-HepB-IPV: Pediarix 11 DTaP-IPV: KINRIX 11 Vaccine Storage and Handling Guide and Storage Vaccine National Center for Immunization and Respiratory Disease DTaP-IPV/Hib: Pentacel 11 Rotavirus Vaccines RV1: ROTARIX 53 RV5: RotaTeq 53 Tetanus Toxoid Vaccine TT: Tetanus Toxoid 57 Vaccine Storage and Handling Guide ——————————————————————————————
    [Show full text]
  • An Overview of COVID Vaccine Clinical Trial Results & Some Challenges
    An overview of COVID vaccine clinical trial results & some challenges DCVMN Webinar December 8th, 2020 Access to COVID-19 tools ACCESSACCESS TO TOCOVID-19 COVID-19 TOOLS TOOLS (ACT) (ACT) ACCELERATOR ACCELERATOR (ACT) accelerator A GlobalA GlobalCollaboration Collaboration to Accelerate tothe AccelerateDevelopment, the Production Development, and Equitable Production Access to New and Equitable AccessCOVID-19 to New diagnostics, COVID-19 therapeutics diagnostics, and vaccines therapeutics and vaccines VACCINES DIAGNOSTICS THERAPEUTICS (COVAX) Development & Manufacturing Led by CEPI, with industry Procurement and delivery at scale Led by Gavi Policy and allocation Led by WHO Key players SOURCE: (ACT) ACCELERATOR Commitment and Call to Action 24th April 2020 ACT-A / COVAX governance COVAX COORDINATION MEETING CEPI Board Co-Chair: Jane Halton Co-Chair: Dr. Ngozi Gavi Board Workstream leads + DCVMN and IFPMA-selected Reps As needed – R&D&M Chair; COVAX IPG Chair Development & Manufacturing Procurement and delivery Policy and allocation (COVAX) at scale Led by (with industry) Led by Led by R&D&M Investment Committee COVAX Independent Product Group Technical Review Group Portfolio Group Vaccine Teams SWAT teams RAG 3 COVAX SWAT teams are being set up as a joint platform to accelerate COVID- 19 Vaccine development and manufacturing by addressing common challenges together Timely and targeted Multilateral Knowledge-based Resource-efficient Addresses specific cross- Establishes a dialogue Identifies and collates Coordinates between developer technical and global joint effort most relevant materials different organizations/ challenges as they are across different COVID-19 and insights across the initiatives to limit raised and/or identified vaccines organizations broader COVID-19 duplications and ensure on an ongoing basis (incl.
    [Show full text]
  • Road to Recovery: Recovering from Post-Acute COVID-19 (Long COVID)
    Road to Recovery: Recovering from post-acute COVID-19 (long COVID) Information and Advice Name: _____________________________ Symptoms reported by patients with post-acute (long) COVID-19 2 Recovery from post-acute COVID-19 (long COVID), October 2020 What is COVID-19? Covid-19 is an infectious virus that mainly affects the lungs. It is transmitted through droplets created from sneezing and coughing. The virus enters the body via the nose, mouth and eyes. What is post-acute COVID-19 (long COVID)? It is the term for someone who has not recovered for several weeks or months following the start of symptoms that were suggestive of COVID, whether they were tested for COVID-19 or not. We do not yet know why some people’s recovery takes much longer than others. What are the symptoms of post-acute COVID-19 (long COVID)? The most commonly reported symptoms are: • Fatigue • Muscle, body aches • Difficulty breathing • As well as the physical symptoms listed, it is very common to experience feelings of anxiety and low mood. Controlling shortness of breath Relieving shortness of breath People who have had a respiratory illness can often feel short of breath (SOB) afterwards. Often daily tasks such as walking, getting dressed or doing chores around the house can cause this breathlessness. Feeling like you can’t catch your breath can make you panic or feel frightened. Learning to control these feelings of breathlessness is a skill that will help you to be less troubled by this and enable you to do more. When you are feeling breathless, do not panic.
    [Show full text]
  • Effectiveness of Pfizer-Biontech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
    Morbidity and Mortality Weekly Report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 Mark W. Tenforde, MD, PhD1; Samantha M. Olson, MPH1; Wesley H. Self, MD2; H. Keipp Talbot, MD2; Christopher J. Lindsell, PhD2; Jay S. Steingrub, MD3; Nathan I. Shapiro, MD4; Adit A. Ginde, MD5; David J. Douin, MD5; Matthew E. Prekker, MD6; Samuel M. Brown, MD7; Ithan D. Peltan, MD7; Michelle N. Gong, MD8; Amira Mohamed, MD8; Akram Khan, MD9; Matthew C. Exline, MD10; D. Clark Files, MD11; Kevin W. Gibbs, MD11; William B. Stubblefield, MD2; Jonathan D. Casey, MD2; Todd W. Rice, MD2; Carlos G. Grijalva, MD2; David N. Hager, MD, PhD12; Arber Shehu, MD12; Nida Qadir, MD13; Steven Y. Chang, MD, PhD13; Jennifer G. Wilson, MD14; Manjusha Gaglani, MBBS15,16; Kempapura Murthy, MPH15; Nicole Calhoun, LMSW, MPA15; Arnold S. Monto, MD17; Emily T. Martin, PhD17; Anurag Malani, MD18; Richard K. Zimmerman, MD19; Fernanda P. Silveira, MD19; Donald B. Middleton, MD19; Yuwei Zhu, MD2; Dayna Wyatt2; Meagan Stephenson, MPH1; Adrienne Baughman2; Kelsey N. Womack, PhD2; Kimberly W. Hart2; Miwako Kobayashi, MD1; Jennifer R. Verani, MD1; Manish M. Patel, MD1; IVY Network; HAIVEN Investigators On April 28, 2021, this report was posted as an MMWR Early ≥65 years. Vaccination is a critical tool for reducing severe Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 in groups at high risk. Adults aged ≥65 years are at increased risk for severe outcomes Randomized clinical trials of vaccines that have received an from COVID-19 and were identified as a priority group to EUA in the United States showed efficacy of 94%–95% in receive the first COVID-19 vaccines approved for use under preventing COVID-19–associated illness (4,5).§ However, an Emergency Use Authorization (EUA) in the United States hospitalization is a rare outcome among patients with (1–3).
    [Show full text]
  • COVID-19 Vaccine Storage & Handling
    COVID-19 Vaccine Storage & Handling Brooke Zeringue, Adrienne Whitney, & Robert Starszak Louisiana Department of Health Office of Public Health Immunization Program • Everyone (16 years and older) can be vaccinated. Louisiana Order COVID-19 vaccine in LINKS. Second COVID-19 doses are not automatically ordered. You must Vaccination order every dose you need. Guidelines All vaccine doses administered must be entered into LINKS within 24 hours and inputted as administered, NOT historical. COVID-19 Vaccine Delivery Storage & Handling for Moderna COVID-19 Vaccine: Direct from McKesson Vaccine will arrive frozen Larger quantities Thermal Shipper Storage & Handling for Pfizer- BioNTech COVID-19 Vaccine: Direct from Shipped in thermal shipping container Pfizer Vaccine arrives frozen Larger quantities Storage & Handling for Moderna COVID-19 Vaccine: Morris & Dickson Vaccine will arrive thawed Smaller Quantities Johnson & Johnson (Janssen) COVID-19 Vaccine Vaccine Type: • Viral Vector Vaccine Age indication: Overview of • 18 years or older. the Johnson & Dose & Route: Johnson • 0.5 mL; intramuscular COVID-19 Schedule: Vaccine • Single dose Dose Preparation: • 5 doses per vial Johnson & Johnson | STORING VACCINE VIALS Refrigerator 2°C to 8°C (36°F to 46°F) • Store up to the expiration date • DO NOT store frozen • Protect from light • You can find the expiration date at vaxcheck.jnj Johnson & Johnson | ADMINISTERING • Keep refrigerated until thawed (if arrived frozen). Refrigerator • PUNCTURED VIALS: Viable up to 6 hours 2°C to 8°C (36°F to 46°F) • If arrived frozen and needed immediately, thaw for Room 1 to 2 hours. • UNPUNCTURED VIALS: Viable up to 12 hours kept Temperature at 9°C to 25°C (47°F to 77°F) • PUNCTURED VIALS: Viable up to 2 hours Up to 25°C (Up to 77°F) Johnson & Johnson | ADMINISTERING Visually inspect the Before withdrawing each Johnson & Johnson COVID- dose of vaccine, carefully 19 vaccine vials for other mix the contents by Each dose must contain 0.5 particulate matter and/or swirling gently in an upright mL of vaccine.
    [Show full text]